Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction

• Published in: JBRA assisted reproduction Vol. 21; no. 2; pp. 67 - 69
• Main Authors: Souza, Priscila Morais Galvão, Carvalho, Bruno Ramalho de, Nakagawa, Hitomi Miura, Rassi, Thalita Reis Esselin, Barbosa, Antônio César Paes, Silva, Adelino Amaral
• Format: Journal Article
• Language: English
• Published: Brazil Sociedade Brasileira de Reprodução Humana (Brazilian Society of Assisted Reproduction) 2017; Brazilian Society of Assisted Reproduction
• Subjects: Adult; Female; Follicle Stimulating Hormone - therapeutic use; Follicle Stimulating Hormone, Human - therapeutic use; Gonadotropin-Releasing Hormone - antagonists & inhibitors; Humans; Menotropins - therapeutic use; Original; Ovulation Induction - methods; Ovulation Induction - statistics & numerical data; Patient Compliance; Pregnancy; Pregnancy Outcome; Retrospective Studies; Corifollitropin alfa; in vitro fertilization; gonadotropins; assisted reproductive technology; ovulation induction
• ISSN: 1518-0557; 1517-5693; 1518-0557
• DOI: 10.5935/1518-0557.20170017

This study aimed to compare the outcomes of controlled ovarian stimulation (COS) with corifollitropin alfa versus daily recombinant follicle-stimulating hormone (rRFSH) or highly purified human menopausal gonadotropin (HP-HMG) in patients undergoing in vitro fertilization (IVF) cycles based on gonadotropin-releasing hormone (GnRH) antagonist protocols. The primary endpoints were total number of oocytes and mature oocytes. This retrospective study looked into 132 controlled ovarian stimulation cycles from IVF or oocyte cryopreservation performed in a private human reproduction center between January 1 and December 31, 2014. Enrollment criteria: women aged < 40 years submitted to COS with corifollitropin alfa 100µg or 150µg (n = 26) and rFSH or HP-HMG in the first seven days of treatment with daily doses of 150-225 IU (n = 106); all subjects were on GnRH antagonist protocols. The groups had similar mean ages and duration of stimulation. The mean number ± standard deviation of total aspirated oocytes and MII oocytes was 11.9±10 and 10.3±7.9 in the corifollitropin alfa group, and 10.9±7.2 and 8.6±5.7 in the group on rFSH or HMG (p>0.05). There were no significant differences in fertilization (76.9% vs. 76.8%, p=1.0), biochemical pregnancy (66.7% vs. 47.2%, p=0.1561) or embryo implantation rates (68.7% vs. 50%, p=0.2588) between the groups using corifollitropin alfa and rFSH or HMG, respectively. Corifollitropin alfa seems to be as effective as rFSH or HP-HMG when used in the first seven days of ovulation induction for patients undergoing assisted reproduction in GnRH antagonist protocols.